Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595003 | 0.82 | CTSL (0.53) | CTSLCTSBADORA3SMN1; SMN2YTHDC1 | |
| SCHEMBL4911813 | 0.74 | ADORA2A (0.60) | ADORA2AADORA3 | |
| SCHEMBL16331916 | 0.69 | CTSL (0.61) | ADORA2ACTSLCTSBADORA3ADORA1 | |
| SCHEMBL3609725 | 0.69 | ADORA1 (0.59) | ADORA2ACTSLCTSBADORA3ADORA1 | |
| SCHEMBL16626233 | 0.67 | EGLN1 (0.67) | ADORA2AEHMT2 | |
| SCHEMBL627355 | 0.67 | EGLN1 (0.67) | ADORA2A | |
| SCHEMBL2548172 | 0.67 | ADORA2A (1.00) | ADORA2AADORA3ADORA1 | |
| SCHEMBL2550832 | 0.67 | ADORA2A (0.77) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14992776 | 0.67 | EGLN1 (0.51) | ADORA2AEHMT2 | |
| SCHEMBL627346 | 0.67 | EGLN1 (0.69) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2010522720-A | — | — | 2010-07-08 | — | — | JP | claimed |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEURO SEARCH A/S/ (DK) | 2010-06-17 | — | — | US | claimed |
| EP-2132208-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2009-12-16 | — | — | EP | claimed |
| WO-2008116911-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | claimed |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEURO SEARCH A/S/ (DK) | 2010-06-17 | — | — | US | disclosed |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEURO SEARCH A/S/ (DK) | 2010-06-17 | — | — | US | disclosed |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEURO SEARCH A/S/ (DK) | 2010-06-17 | — | — | US | disclosed |
| EP-2132208-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116911-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116911-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | ADORA2A 295/4885CTSL 4083/4885CTSB 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.